Endoscopic electrochemotherapy for Oesophageal cancer: a phase I clinical study

Publication: Endoscopy International Open
Publication Date: May 2018
Author(s): Charlotte Egeland, Lene Baeksgaard, Helle Hjorth Johannesen, Johan Löfgren, Christina Caroline Plaschke, Lars Bo Svendsen, Julie Gehl, and Michael Patrick Achiam

Background and study aims

Oesophageal cancer is on the rise in the western world and the disease has a poor 5-year survival prognosis below 20 %. Electrochemotherapy is a treatment where a chemotherapeutic drug is combined with locally applied electrical pulses, in order to increase the drug’s cytotoxicity in malignant cells. This study presents the first results with electrochemotherapy treatment in esophageal cancer.

Patients and methods

In this first-in-human trial, six patients with advanced Oesophageal cancer were treated with electrochemotherapy using intravenous bleomycin. All side effects and adverse events (AEs) were registered and the patients were later evaluated with gastroscopy and 18F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging (18F-FDG PET/MRI).


Treatment was well tolerated, main AEs being nausea, vomiting, oral thrush, pneumonia, retrosternal pain, fever, and hoarseness. No serious complications were observed. Five patients had a visual tumor response confirmed by gastroscopy. In two cases, these findings were confirmed with 18F-FDG PET/MRI as it revealed a reduction of total tumor mass.


Electrochemotherapy in patients with advanced oesophageal cancer was conducted without major safety concerns. This study paves the way for larger studies, which may further elucidate response rates for and side effects of this new treatment.

Share the News